Tetrahydrobiopterin and Endothelial Dysfunction in Cardiovascular Diseases

Endothelial Progenitor Cell Dysfunction in Polycystic Ovary Syndrome: Implications for The Genesis of Cardiovascular Diseases

Tetrahydrobiopterin Improves Endothelial Function in Cardiovascular Disease: A Systematic Review

Background. Tetrahydrobiopterin (BH4) is a cofactor of nitric oxide synthase (NOS). Nitric oxide (NO) bioavailability is reduced during the early stage of vascular diseases, such as coronary artery disease, hypercholesterolemia, hypertension, and diabetic vasculopathy, and even throughout the entire progression of atherosclerosis. Methods. A literature search was performed using electronic data...

Inhibition of Aberrant MicroRNA-133a Expression in Endothelial Cells by Statin Prevents Endothelial Dysfunction by Targeting GTP Cyclohydrolase 1 in Vivo

BACKGROUND GTP cyclohydrolase 1 (GCH1) deficiency is critical for endothelial nitric oxide synthase uncoupling in endothelial dysfunction. MicroRNAs (miRs) are a class of regulatory RNAs that negatively regulate gene expression. We investigated whether statins prevent endothelial dysfunction via miR-dependent GCH1 upregulation. METHODS Endothelial function was assessed by measuring acetylchol...

NO or H(2)O(2) for endothelium-dependent vasorelaxation: Tetrahydrobiopterin makes the difference.

Rapid adaptation of the diameter of blood vessels is an important regulatory mechanism for regulating blood pressure and for limiting tissue damage resulting from wounding or ischemia. Endothelial cells contribute to vasoregulation by the production of potent vasodilators. Loss or reduction of endothelium-dependent vasorelaxation is one of the reflections of endothelial dysfunction, an early ha...

COMPREHENSIVE INVITED REVIEW Tetrahydrobiopterin in Cardiovascular Health and Disease

Tetrahydrobiopterin (BH4) functions as a cofactor for several important enzyme systems, and considerable evidence implicates BH4 as a key regulator of endothelial nitric oxide synthase (eNOS) in the setting of cardiovascular health and disease. BH4 bioavailability is determined by a balance of enzymatic de novo synthesis and recycling, versus degradation in the setting of oxidative stress. Augm...